Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evercore ISI Group Downgrades AN2 Therapeutics to In-Line, Lowers Price Target to $7

Author: Benzinga Newsdesk | February 12, 2024 01:54pm
Evercore ISI Group analyst Liisa Bayko downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and lowers the price target from $25 to $7.

Posted In: ANTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist